Scangos, Katherine W. http://orcid.org/0000-0001-7983-7767
Khambhati, Ankit N. http://orcid.org/0000-0001-6182-4677
Daly, Patrick M.
Makhoul, Ghassan S.
Sugrue, Leo P.
Zamanian, Hashem http://orcid.org/0000-0003-4515-8875
Liu, Tony X. http://orcid.org/0000-0001-9334-8492
Rao, Vikram R. http://orcid.org/0000-0002-6389-2638
Sellers, Kristin K. http://orcid.org/0000-0002-0517-2296
Dawes, Heather E.
Starr, Philip A. http://orcid.org/0000-0003-2733-4003
Krystal, Andrew D. http://orcid.org/0000-0002-6702-781X
Chang, Edward F. http://orcid.org/0000-0003-2480-4700
Article History
Received: 3 March 2021
Accepted: 23 July 2021
First Online: 4 October 2021
Competing interests
: A.D.K. consults for Eisai, Evecxia Therapeutics, Ferring Pharmaceuticals, Galderma, Harmony Biosciences, Idorsia, Jazz Pharmaceuticals, Janssen Pharmaceuticals, Merck, Neurocrine Biosciences, Pernix Pharma, Sage Therapeutics, Takeda Pharmaceutical Company, Big Health, Millennium Pharmaceuticals, Otsuka Pharmaceutical and Neurawell Therapeutics. A.D.K. acknowledges support from Janssen Pharmaceuticals, Jazz Pharmaceuticals, Axsome Therapeutics (no. AXS-05-301) and Reveal Biosensors. K.W.S. serves on the advisory board of Nesos. UCSF and E.F.C. have patents related to brain stimulation for the treatment of neuropsychiatric disorders. V.R.R. has served as a paid consultant for NeuroPace but declares no targeted funding from NeuroPace for this study. P.A.S. receives research support from Medtronic. The other authors declare no competing interests.